TAT-10: Efficacy of Actinium-225-labeled Anti-CD33 Antibody in Acute Myeloid Leukemia Correlates with Peripheral Blast Count
Kanazawa, Japan (UroToday.com) This study was conducted in two phases. Phase one had 18 relapsed and refractory acute myeloid leukemia (AML) patients. Patients were treated with a single infusion of Actimab-A, the company’s name for Ac-225 conjugated to the anti-CD33 monoclonal antibody lintuzumab. Doses ranged from 18.5 to 148 kBq/kg and post analysis determined a maximum dose of 111 kBq/kg. In the second trial (18 newly diagnosed patients), were treated with two equal doses at 14 days and 21 days. Total doses ranged from 37 to 148 kB/kq.
TAT-10: Bi-213-anti-EGFR-Mab Therapy of Recurrent Bladder Cancer - A Pilot Study
Kanazawa, Japan (UroToday.com) Patients with non-muscle invasive bladder cancer treated with surgical resection and chemotherapy with Bacillus Calmette-Guerin (BCG) experience up to 40% relapse and require bladder removal. Following successful treatment using Bi-213 labeled Epidermal Growth Factor Reduction (EFGR) Mab in mice, a pilot study was undertaken with 12 human patients (10 male, 2 female).
TAT-10: Targeted Alpha Therapy of Glioblastoma Multiforme: Clinical Experience with Bi213 and Ac225-Substance P
Kanazawa, Japan (UroToday.com) Glioblastoma multiforme (GBM) is a common brain tumor in young men with a poor prognosis of 15 months even with aggressive treatment of surgery, chemotherapy, and external radiation. In this study, the radionuclide is bound in DOTA and linked to Substance P which targets NK1 receptors expressed by GBM. The dose was administered by 1 or 2 catheters into either the tumor or the cranial cavity through the scull penetration remaining from the surgical treatment. PET scan imaging from Ga68-SubstanceP co-injected into the tumor site verified high retention of the radio-isotope.
TAT-10: Dosimetry and Biodistribution of Pb203-AR-RMX in Patients with Somatostatin Expressing Neuroendocrine Tumors: A Clinical Exploratory Study
Kanazawa, Japan (UroToday.com) This is an exploratory study in patients who had received targeted beta therapy to determine the dosimetry and biodistribution using imaging agents Pb203 and Ga68 in preparation for eventual targeted alpha therapy using Pb212. Six patients with confirmed somatostatin-expressing neuroendocrine tumors were recruited.
TAT-10: Ac225-PSMA-617: PSMA Targeting Alpha-Radiation Therapy of Patients with mCRPC
Kanazawa, Japan (UroToday.com) A preliminary study was undertaken to establish the dosage and treatment intervals for Ac225-PSMA-617 treatment for metastatic castration resistant prostate cancer (mCRPC). Fourteen patients were recruited and all had previously received the standard care of androgen deprivation therapy and chemotherapy. Dosimetry estimates were computed from Lu177-PSMA-617 scans.
TAT-10: Radium-223 in Asymptomatic Metastatic Castration Resistance Prostate Cancer Patients Treated in an International Early Access Program (iEAP)
Kanazawa, Japan (UroToday.com) The purpose of this study was to see if there were significant differences in asymptomatic patients at baseline compared to symptomatic patients for early treatment with Ra223. Asymptomatic was defined as no pain and no opioid use. In other selection criteria, malignant lymphadenopathy > 6cm and visceral disease were excluded.
TAT-10: Changes to Alkaline Phosphatase Dynamics and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 in an International Early Access Program
Kanazawa, Japan (UroToday.com) Identifying a reliable marker that is highly correlated with improved overall survival and reduced adverse events for Ra223 treatment would greatly aid the clinical management of metastatic castration-resistant prostate cancer (mCRPC) patients. Bone alkaline phosphate (ALP) is a marker for osteoblasts in bone tissue.